Skip to main content
Journal ArticleOPEN ACCESS

Venetoclax: a primer

  • Roberts A
Blood Advances (2017) 1(7) 467-467
DOI: 10.1182/bloodadvances.2017000547
N/ACitations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

> > > Venetoclax is a BH3-mimetic small molecule drug that directly and selectively inhibits BCL-2. BCL-2 is highly expressed in many hematologic malignancies and is the predominant prosurvival protein in diseases such as chronic lymphocytic leukemia (CLL), follicular lymphoma, and mantle cell

Cite

CITATION STYLE

APA

Roberts, A. W. (2017). Venetoclax: a primer. Blood Advances, 1(7), 467–467. https://doi.org/10.1182/bloodadvances.2017000547

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free